
30-Year Study: Genotropin’s Impact on Cardiovascular Health in American Males with GHD
Reading Time: 2 minutes Introduction Growth hormone deficiency (GHD) in adults is associated with a range of metabolic and cardiovascular complications. Genotropin, a recombinant human growth hormone, has been widely used to treat GHD. However, the long-term cardiovascular outcomes of its use remain a topic of significant interest and concern. This article presents a comprehensive 30-year cohort analysis focusing on the cardiovascular health of American males treated with Genotropin for GHD. Study Design and Methodology This study followed a cohort of 500 American males diagnosed with GHD who initiated Genotropin therapy between the ages of 18 and 35. Participants were monitored annually for cardiovascular...